CommercialPrior AuthHigh impact
Spinal Cord Stimulation (CPB 0194, reviewed 2026-05-21)
Aetna·Pain Management, Neurosurgery, Neurology +3 more·Medical Policy
Effective date
May 21, 2026
We identified it
Aug 17, 2026
Summary
Aetna updated its Spinal Cord Stimulation (SCS) medical policy (CPB 0194, reviewed 2026-05-21) establishing comprehensive medical necessity criteria for SCS trials and implantation across multiple chronic pain indications. The policy clarifies coverage for standard, high-frequency, burst, and DTM stimulators; defines specific trial success thresholds (50% pain reduction); and explicitly excludes certain off-label uses as experimental. Key requirements include multidisciplinary evaluation, 6-month conservative treatment failure, psychological clearance, and specific imaging/functional assessment documentation.
Action Required
By 2026-05-21 (Policy effective date): Billing and clinical teams must implement the following:
REQUIREMENTS:
1. Update prior authorization workflows to enforce ALL medical necessity criteria before claim submission, including: multidisciplinary evaluation confirmation, 6-month conservative treatment documentation (at least 3 medication classes + formal physical therapy 6+ weeks + psychological therapy), psychological/psychiatric clearance, Oswestry Disability Index (ODI) ≥21%, and advanced imaging (CT/MRI) clearance.
2. Billing team must configure system rules to require: (a) Trial success documentation (50%+ pain reduction, 3-7 day trial period with lead pull notes) BEFORE approving implantation claims; (b) For FBSS cases, documentation of prior spinal surgery on imaging; (c) For intractable angina, angiographic documentation, NYHA Class III/IV, optimal pharmacotherapy documentation (≥2 anti-anginal agents at max tolerated doses for ≥1 month), and reversible ischemia testing.
3. Clinical staff must ensure all trial documentation includes specific pain reduction percentage (50%+ threshold) and trial duration (3-7 days) in charts before billing implantation.
4. Update encounter templates and prior auth request forms to capture all mandatory criteria, particularly ODI scoring and conservative treatment details.
5. Flag for denial review: (a) Repeat trials without documented extenuating circumstances (lead migration, infection, anatomic difficulties); (b) Battery replacements for paresthesia; (c) Any standard-to-high-frequency/burst/DTM device replacements in functioning patients; (d) Electrode/lead quantities exceeding limits (16 electrodes/2 percutaneous/1 paddle for trials; 16 electrodes/4 percutaneous for implants); (e) Cervical DCS for any indication OTHER than CRPS; (f) Any indication not explicitly listed as medically necessary.
6. For DRG stimulators (Axium), confirm same general criteria apply when claimed for CRPS lower limbs.
7. Communicate to providers that experimental/investigational uses (cervical DCS for tremor, migraine, CRPS at non-extremity sites, chronic pancreatitis, abdominal/visceral pain, etc.) will NOT be covered.
8. If claims are submitted without complete documentation of these criteria, they will be denied for insufficient medical necessity documentation. Failure to update workflows will result in widespread claim rejections.